Eraldor

There is no image.

Acetaminophen

Method of action: Analgesic, Anti-Inflammatory, Antipyretic, Pain Reliever

Treatment option: Arthralgia, Period Pain, Backache, Pain, Sore Throat, Earache, Headache, Influenza, Toothache, Fever

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Eraldor

Quick Facts: Eraldor (Acetaminophen)

Property	Description
Active Ingredient	Acetaminophen (Paracetamol, APAP)
Forms	Tablet, Capsule, Solution, Suppository, Intravenous
Pharmacological Class	Non-Opioid Analgesic and Antipyretic
Common Use	Symptomatic relief of pain and fever
Origin	Synthetic Compound

What is Eraldor?

Eraldor is the established medicinal product name for preparations containing the active ingredient Acetaminophen, internationally recognized as Paracetamol. This widely used, single-entity product is produced synthetically and acts systemically to offer foundational symptomatic relief from pain and fever.

What Type of Medicine is Eraldor and What Does It Do?

Eraldor is classified as a non-opioid analgesic (for pain relief) and an antipyretic (for fever reduction). Its core therapeutic purpose is the management of common physical discomforts associated with these two symptoms, such as the general body aches and elevated temperature often accompanying colds. Acetaminophen's primary mechanism is concentrated in the central nervous system, meaning it alleviates pain and reduces fever without exerting significant anti-inflammatory effects in peripheral body tissues. This medicine achieves relief by affecting the way pain signals are processed in the brain, a mechanism recognized for its reliable efficacy across patient groups. Its classification distinguishes it from nonsteroidal anti-inflammatory drugs (NSAIDs) because its mechanism offers a different approach to symptom management with a well-established safety profile.

Composition and Forms of Eraldor

The entire composition of Eraldor is built upon its active compound, Acetaminophen. This compound is a synthetic substance that does not occur naturally. Eraldor is manufactured in several standard dosage forms for versatility, including solid oral preparations such as tablets and capsules, and liquid preparations like oral solutions. The brand Eraldor is typically positioned as an over-the-counter (OTC) option, often featuring formulations tailored for specific patient groups, such as flavored oral solutions aimed at pediatric use, ensuring ease of administration for children. Furthermore, specialized rectal (suppository) and intravenous (parenteral) forms are also available in hospital settings. It is characterized as an effective over-the-counter substance for its indicated purposes.

Regulatory References

What side effects are possible with Eraldor?

Possible Side Effects and Safety Information for Eraldor

This section summarizes the officially documented safety profile of Eraldor, strictly as reported in governmental regulatory sources. As the full, finalized regulatory label for a product named Eraldor is not currently in the public domain of major authorities (e.g., FDA, EMA), the definitive adverse reaction profile must be confirmed by consulting the drug's official package insert.

Adverse Reaction Scope	Description from Regulatory Texts
Key Adverse Reaction Categories	Specific categories (e.g., by frequency, severity, or system-organ class) are pending the release of the official regulatory documentation.
Common Adverse Reactions	Officially defined common (very common / common) reactions are not yet established. Clinical experience reported in studies for similar compounds often includes systemic effects such as headache, fatigue, or gastrointestinal upset.
Serious Adverse Reactions	Specific serious events requiring immediate attention are defined by the official prescribing information; this may include rare, clinically significant events or severe forms of common reactions.

Safety Classifications (High-Level)

Regulatory Basis: The authoritative safety framework (e.g., EMA/ICH frequency bands, FDA system-organ classes) will be explicitly stated in the final governmental approval document.
Population-Specific Safety: Any required adjustments or restrictions for specific patient populations (e.g., those with renal or hepatic impairment, pregnant individuals, or the elderly) are detailed in the official safety section.
Restrictions and Limitations: Official labels contain required statements regarding safety limitations, such as situations where use is restricted or monitoring is mandatory (e.g., required laboratory tests, discontinuation upon specific adverse event development).

Connection to the Overall Safety Profile

The full safety profile of Eraldor is structured around the adverse reaction data collected during clinical trials and post-marketing surveillance, classified according to a formal regulatory frequency framework. This official documentation is the sole source for defining the complete spectrum of risks, from the most frequent, mild events to the rare, clinically significant reactions. Adherence to these limitations and monitoring requirements defined in the regulatory text is the basis for safe use.

Overdose and Emergency Response

The official regulatory profile for Eraldor (Acetaminophen) overdose centers on the documented risk of severe hepatic injury (hepatotoxicity), which can progress to Acute Liver Failure and potentially lead to death. The initial clinical presentation of an overdose is often nonspecific, including symptoms such as nausea, vomiting, or malaise.

Critically, official documents state that initial signs may be absent entirely for the first day, meaning the severity of the overdose cannot be determined by the current appearance of symptoms. Later manifestations of severe toxicity can include jaundice (yellowing of the skin) and confusion.

Regulatory guidance strictly mandates that individuals seek immediate medical attention or contact a Poison Control Center right away for all suspected ingestions, regardless of whether symptoms are present. Prompt medical attention is critical because the primary risk of toxicity is severe, time-sensitive liver damage.

The official management procedure is defined by the administration of the antidote N-acetylcysteine (NAC) and continuous monitoring of hepatic and renal function. Official documentation also notes that individuals with pre-existing conditions, such as hepatic impairment or alcoholism, may exhibit increased susceptibility to severe toxic effects.

Therapeutic Uses of Eraldor

What Eraldor Treats: Main Uses and Benefits

Eraldor provides symptomatic relief across two core therapeutic domains: managing pain and controlling fever. It is applied in situations involving symptomatic discomfort where short-term supportive assistance is needed, assisting with maintaining functional stability when symptoms interfere with routine activities.

The medication is commonly used to help with mild to moderate painful physical discomforts stemming from common, acute episodes. This helps address symptoms related to physical discomfort such as headache, toothache, general muscle aches, backache, and menstrual cramps. It also plays a role in managing systemic temperature elevation (fever) that often clusters with other symptoms like body aches associated with colds or influenza. The benefit is to provide support that helps ease the overall symptom burden and contribute to improved comfort during periods of heightened symptoms.

“It is commonly used when symptoms intensify and supportive relief is needed.”

Eraldor is considered relevant for providing symptomatic assistance to a wide range of patients, including children, infants, and older adults. Its profile supports its use for pain and fever management during pregnancy and breastfeeding, and is applicable for initial symptom management in these sensitive groups when temporary assistance in symptom stabilization is required.

Quick Fact: Relief for Acute Discomfort
Symptom Category	Symptoms related to physical discomfort
Severity Relevance	Mild to moderate pain
Primary Benefit	Helps maintain a sense of stability when symptoms are more noticeable

Regulatory References

Australian government health authority

Eligibility and Restrictions for Use

Who Can and Cannot Use Eraldor?

Population eligibility for Eraldor (Acetaminophen/Paracetamol) is defined by official regulatory documentation, establishing mandatory exclusions and conditional restrictions.

Eligibility Scope

Classification	Population
Contraindicated	Individuals with known hypersensitivity to Acetaminophen or any component of the formulation; Patients with severe active liver disease or severe hepatocellular insufficiency.
Restricted/Conditional Use	Patients with severe renal impairment (creatinine clearance le 30 mL/min); Those with chronic alcohol abuse, chronic malnutrition, or G6PD deficiency.
Established Use	Adults, adolescents, and most pediatric patients (subject to minimum age/weight rules); Lactating women.

Pregnancy and Specific Rules

Use during pregnancy is permitted by regulatory authorities but is officially restricted to the lowest effective dose, for the shortest duration, and at the lowest possible frequency. The medicine is generally considered compatible with breastfeeding. Eligibility for the pediatric population is highly dependent on formulation and minimum age/weight thresholds, with use typically restricted in the youngest infants.

What should I know about interactions with other medicines?

Co-administration of Eraldor with other substances is officially documented by regulatory authorities across several categories, primarily affecting metabolism and exposure.

Contraindicated Combinations and High-Risk Substances

The most critical restriction is the formal prohibition against taking Eraldor concurrently with any other medicinal product that contains acetaminophen or paracetamol. This restriction is due to the cumulative and severe risk of liver damage. Additionally, regulatory documents note that chronic, excessive alcohol intake (three or more drinks per day) significantly increases the hazard of hepatotoxicity. For patients with a documented history of chronic alcoholism, specific dosage limitations may apply. Severe active liver disease is also a condition that heightens the risk of interaction-related liver injury.

Exposure-Altering Interactions

Several medicines are officially listed as modifying Eraldor’s systemic exposure. Co-administration with probenecid is documented to reduce Eraldor's clearance, which can lead to higher plasma concentrations. Conversely, the bile acid sequestrant cholestyramine reduces Eraldor’s absorption. To mitigate this effect, a mandatory timing rule requires the administration of these two medicines to be separated by at least one hour. Medicines that accelerate gastric emptying, such as metoclopramide or domperidone, increase the rate of Eraldor's absorption.

Pharmacodynamic Interactions

Prolonged, regular daily co-administration with warfarin and other coumarins is officially associated with an enhanced anticoagulant effect, increasing the risk of bleeding. The interaction with liver enzyme-inducing agents, including medicines like phenytoin or rifampicin, may increase the formation of a potentially toxic metabolite.

Mechanism of Action

Eraldor (a proxy for Acetaminophen) exerts its effects primarily within the central nervous system (CNS), demonstrating a high degree of selective action compared to peripheral tissues. Its molecular interaction is characterized as an indirect inhibitor of prostaglandin H2 synthase (PGHS), also known as cyclooxygenase (COX), particularly the COX-2 isoform in environments with low peroxide tone.

The molecule acts as a reducing cosubstrate at the peroxidase (POX) site of the PGHS enzyme, which prevents the conversion of the ferric Fe^3+ heme to its activated ferryl radical state. This, in turn, disrupts the formation of the tyrosine-385 radical required for the cyclooxygenase activity that converts arachidonic acid to prostaglandin G2 ( PGG2), thus inhibiting the subsequent synthesis of prostaglandin E2 ( PGE2).

A separate pathway involves a central metabolite, AM404, which functions as an indirect agonist of the cannabinoid CB1 receptor and modulates the transient receptor potential vanilloid-1 (TRPV1) receptor. This activity, coupled with Eraldor's potentiation of descending serotonergic pathways that originate in the periaqueductal gray matter, results in the modulation of central nociceptive signaling. System-level physiological consequences include the lowering of the hypothalamic set point via reduced central PGE2 levels, which controls thermoregulation.

Dosage and Administration Information

How to Use Eraldor

Eraldor (Acetaminophen) use follows specific parameters concerning the dose, frequency, and method of administration. The product is utilized via the oral route (tablets, capsules, solutions), the rectal route (suppository), and intravenous (IV) infusion in specialized healthcare settings. The choice of route and form dictates the specific usage procedure.

The standard adult single dose for immediate-release forms typically ranges from 650 mg to 1,000 mg, with doses to be separated by a minimum of 4 hours. The maximum total daily dose of acetaminophen from all sources is established not to exceed 4,000 mg in a 24-hour period. For low-weight adults (< 50 kg) and pediatric patients, dosing is determined strictly by weight to prevent exceeding appropriate limits. Furthermore, patients with hepatic or severe renal impairment require dose reduction or extension of the minimum dosing interval.

Administration protocols vary by formulation. The intravenous form is administered as a controlled 15-minute infusion, and careful preparation is required for smaller doses. Certain extended-release oral tablets must be swallowed whole and are not to be crushed, chewed, or dissolved. The medicine is intended for short-term use, with standard parameters advising against continuous use beyond 10 days for pain or 3 days for fever unless under medical supervision. This structured use protocol ensures standardized administration within established boundaries.

Recent Clinical Evidence

Research evidence / Overview of studies for Eraldor

️ Evidence for use in Reducing Fever (Antipyresis)

Research exploring how Eraldor was studied for how it relates to elevated body temperature in short-term Randomized Controlled Trials (RCTs). These studies included diverse populations, such as adults, infants, and children presenting with fever. Researchers were interested in how systemic or functional imbalance was affected and specifically examined outcomes such as the degree of body temperature reduction and the time until the temperature began to decrease.

The findings from these trials and subsequent Systematic Reviews describe patterns observed in the measured outcomes during the study period. The body of evidence for this indication is categorized as High; this reflects the large volume of consistent RCTs that studies monitored in this area. Long-term outcomes related to sustained antipyresis are not relevant to this indication and are not well characterized in the existing research.

Evidence for use in Managing Acute Pain

Research exploring the use of Eraldor for outcomes related to physical discomfort (mild to moderate acute pain) was evaluated in a significant volume of studies, including placebo-controlled RCTs and regulatory overviews. This evidence explored how outcomes related to physical discomfort change over time, such as headache, toothache, and general muscle aches. The overall body of data highlights changes measured during the study periods for acute episodes.

Evidence for Adjunctive Use in Severe Pain

Eraldor was studied for its use in combination with other analgesics, such as opioids, particularly in acute care and hospitalized settings following surgery or trauma. These trials examined the role of Eraldor in a multi-modal pain approach. Study outcomes explored patterns in the consumption of opioid medication and overall pain scores. However, the follow-up durations were limited, often restricted to the initial hospital stay.

Evidence in Special Populations

Research has explored the medicine’s use across various groups, including pediatric patients. Studies was evaluated in infants and children, contributing to the broader evidence landscape for these age groups.

Research explored the medicine’s use during pregnancy in specific detail, primarily relying on large-scale observational research, such as cohort studies, as RCTs are not conducted in this area. Outcomes research examined focused on the association between maternal Eraldor use during gestation and subsequent neurodevelopmental diagnoses in the child. Observational data regarding use during pregnancy findings were mixed, and scientific debate is ongoing due to the difficulty in establishing causation. Certainty remains low in some published reviews.

What is Still Uncertain in the Research

The scientific literature highlights several areas where the evidence base for Eraldor contains limitations or gaps.

Chronic Pain Conditions: Evidence quality varies across studies regarding its use as a single agent for many chronic conditions; the primary research strength is in acute or disruptive episodes.
Long-Term Patterns: Research exploring short-term symptom changes provides context, but the long-term effects are not fully established, particularly concerning symptom patterns over extended periods of time.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Eraldor (FAQ)

Q: Does Eraldor interact with alcohol?

Regulatory labels contain a warning about consuming alcohol while using Eraldor. The official product information specifies that consuming three or more alcoholic drinks every day may increase the risk of severe liver damage. This warning is related to the potential for increased risk of severe liver damage.

Q: Is there a maximum time I should take Eraldor for fever?

Official over-the-counter product information advises that the medicine should be discontinued and a healthcare provider consulted if a fever worsens or lasts for more than 3 days. This limitation is in place to ensure that prolonged symptoms are evaluated by a professional, as it may indicate an underlying condition requiring different treatment.

Q: What are the most common side effects of Eraldor?

The official safety labels are required to clearly communicate the most serious risks, such as an Allergy Alert for severe skin reactions and the Liver Warning. The official safety profile provides a detailed classification of adverse reactions, including those that are less serious or more frequent, as reported in clinical data from trials and post-marketing surveillance.

Q: Can I crush the Eraldor tablet if I have trouble swallowing?

Official directions for use specify that extended-release tablets must be swallowed whole and should never be crushed, chewed, or dissolved. This ensures the medicine releases as intended for that specific formulation. For standard immediate-release tablets or other forms, individuals should follow the specific directions provided for their particular preparation.

Q: How long does it take for Eraldor to start working after I take it?

Official clinical summaries for the oral forms of Eraldor generally report an onset of pain relief. The initial effect is often reported to begin within 15 to 30 minutes following the dose. The exact time may vary between individuals and formulations.

Q: What should I do if I miss a dose of Eraldor?

For use on an as-needed basis, a dose is typically not considered 'missed.' For regular dosing schedules, official patient information states that if a dose is missed, it should be taken as soon as it is remembered. However, the missed dose should be skipped if it is nearly time for the next scheduled dose to prevent taking a double amount.

Q: Are there any dietary restrictions or foods to avoid while taking Eraldor?

According to official product information, there are no general food restrictions or specific diets that need to be followed while taking Eraldor. Unless a healthcare professional has advised otherwise for a specific medical condition, patients are generally advised to continue with their normal diet.

Q: What is the difference between Eraldor and an NSAID?

The product's mechanism of action helps clarify its distinction from nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen. Eraldor is mainly an analgesic (pain reliever) and antipyretic (fever reducer) that works primarily in the central nervous system. Unlike NSAIDs, Eraldor does not exhibit significant anti-inflammatory activity throughout the peripheral body tissues.

How should Eraldor be stored and disposed of?

Storage Recommendations

Condition	Details
Temperature	Store Eraldor at controlled room temperature, typically between 68 F and 77 F (20 C and 25 C). Avoid extreme heat or freezing.
Environment	Keep the medicine in its original container, protected from excessive moisture and light. Do not store it in the bathroom or near a kitchen sink.
Safety	Always keep Eraldor out of the reach of children and pets to prevent accidental ingestion or misuse.

Disposal of Unused or Expired Medication

Proper disposal is essential to prevent harm. The preferred method for getting rid of unused or expired Eraldor is through a medicine take-back program, which may be available at local pharmacies or community collection events. If a take-back program is unavailable and Eraldor is not on an established list of flushable medications, you may dispose of it in the household trash. To do this, mix the medicine with an undesirable substance, such as dirt or used coffee grounds, place the mixture in a sealed bag or container, and discard it. Remove all personal information from the prescription label before discarding the original packaging.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Ecuador

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z